🇯🇵·20h agoIndustry
Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026（Link to Otsuka America Pharmaceutical website）
Publisher
O
Otsuka Holdings RSS
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Otsuka Holdings RSS
- Region
- Japan
- Scope
- Industry
- Published
- July 27, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on otsuka-us.com
Leave the platform to read the original full article on the publisher site.
Source: Otsuka Holdings RSS
Scope: Industry
Related coverage